Cohen Sem E, Niemeijer Marisa J, Zantvoord Jasper B, van Wingen Guido A, Mocking Roel J T, Denys Damiaan
Amsterdam UMC location University of Amsterdam, Department of Psychiatry, Amsterdam, The Netherlands.
Amsterdam Neuroscience, Amsterdam, The Netherlands.
Mol Psychiatry. 2025 Jun 27. doi: 10.1038/s41380-025-03092-z.
Deep brain stimulation (DBS) is a neuromodulatory intervention for severe, treatment-refractory obsessive-compulsive disorder (OCD). We conducted the first meta-analysis using individual participant outcome data, systematically evaluating (1) efficacy of DBS compared to sham-stimulation in randomized controlled trials (RCTs), (2) adverse events and (3) methodological trial quality.
We conducted a systematic search across multiple databases, including all RCTs comparing DBS with sham in adults with OCD, regardless of stimulation target. We obtained Yale-Brown Obsessive-Compulsive Scale (YBOCS) data for individual participants and performed a two-stage random-effects meta-analysis. We evaluated trial quality using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.
Nine RCTs with small sample sizes were included, resulting in a total sample of 91 patients. Meta-analysis showed a decrease of 5.1 YBOCS points in favor of DBS compared to sham (95% confidence interval, CI, 2.0-8.1, 0.56 Hedges' g). OR was 4.7, 95% CI 1.8-12.2), with a NNT of 3.9. Optimization strategy appeared to impact efficacy, in favor of trials using gradual adjustments of DBS parameters guiding towards maximal improvement (beta 5.1, 95% CI 0.59-9.5, p-value 0.026). Adverse events occurred during surgery, active- and sham trial phases, and follow-up, with hypomania and cognitive problems being the most frequently reported stimulation-related adverse events. GRADE quality of evidence was rated low.
Concluding, we found a significant effect of DBS compared to sham in treating OCD. However, the quality of evidence was low, and heterogeneity was high. Additional, rigorous, sham-controlled evidence could further improve credibility of DBS for OCD.
PROSPERO-REGISTRATION NUMBER: CRD42024546836.
深部脑刺激(DBS)是一种用于治疗严重的、难治性强迫症(OCD)的神经调节干预措施。我们进行了首次使用个体参与者结局数据的荟萃分析,系统地评估了:(1)在随机对照试验(RCT)中,与假刺激相比,DBS的疗效;(2)不良事件;以及(3)试验方法学质量。
我们在多个数据库中进行了系统检索,纳入了所有比较DBS与假刺激治疗成人OCD的RCT,无论刺激靶点如何。我们获取了个体参与者的耶鲁-布朗强迫症量表(YBOCS)数据,并进行了两阶段随机效应荟萃分析。我们使用推荐分级、评估、制定与评价(GRADE)方法评估试验质量。
纳入了9项样本量较小的RCT,总样本量为91例患者。荟萃分析显示,与假刺激相比,DBS组的YBOCS评分降低了5.1分(95%置信区间,CI,2.0 - 8.1,Hedges' g为0.56)。优势比为4.7,95%CI为1.8 - 12.2),需治疗人数为3.9。优化策略似乎会影响疗效,有利于采用逐步调整DBS参数以实现最大改善的试验(β为5.1,95%CI为0.59 - 9.5,p值为0.026)。不良事件发生在手术、主动治疗和假刺激试验阶段以及随访期间,轻躁狂和认知问题是最常报告的与刺激相关的不良事件。GRADE证据质量被评为低等级。
总之,我们发现与假刺激相比,DBS在治疗OCD方面有显著效果。然而,证据质量较低,异质性较高。更多严谨的、采用假刺激对照的证据可能会进一步提高DBS治疗OCD的可信度。
PROSPERO注册号:CRD42024546836。